Earnings History Data for Corcept Therapeutics Incorporated (CORT) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol. It is developing its lead product, CORLUX for the treatment of the psychotic features of psychotic major depression. Corcept Therapeutics Incorporated is headquartered in Menlo Park, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
26-02-2025	AH		CORT	Corcept Therapeutics Incorporated	6,480	0.26	0.37	0.28	Corcept Therapeutics GAAP EPS of $0.26 misses by $0.16, revenue of $181.8M misses by $18.32M [2/26/2025 4:11 PM]	60.00	-3.37 (-5.32%)	62.00	-1.37 (-2.16%)	20.84 - 75.00	1,788,076	1,090,000	11,510
Corcept Therapeutics GAAP EPS of $0.26 misses by $0.16, revenue of $181.8M misses by $18.32M [2/26/2025 4:11 PM] Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update [2025-02-26 04:05PM] Corcept (CORT) Q4 Earnings Report Preview: What To Look For [Feb-25-25 08:00AM]
30-10-2024	AH		CORT	Corcept Therapeutics Incorporated	4,940	0.41	0.27	0.28	Corcept Therapeutics GAAP EPS of $0.41 beats by $0.13, revenue of $182.5M beats by $10.53M [10/30/2024 4:17 PM]	48.97	2.08 (4.44%)	43.75	-3.14 (-6.70%)	20.84 - 50.07	2,179,266	1,190,000	23,468
Corcept Therapeutics GAAP EPS of $0.41 beats by $0.13, revenue of $182.5M beats by $10.53M [10/30/2024 4:17 PM] Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushings Syndrome and Provides Corporate Update [2024-10-30 04:05PM]
29-07-2024	AH		CORT	Corcept Therapeutics Incorporated	3,630	0.32	0.22	0.25	Corcept Therapeutics GAAP EPS of $0.32 beats by $0.10, revenue of $163.8M beats by $8.58M [7/29/2024 4:15 PM]	36.27	-0.26 (-0.71%)	38.75	2.22 (6.08%)	20.84 - 38.98	2,050,982	980,000	18,597
Corcept Therapeutics GAAP EPS of $0.32 beats by $0.10, revenue of $163.8M beats by $8.58M [7/29/2024 4:15 PM]
01-05-2024	AH		CORT	Corcept Therapeutics Incorporated	2,420	0.25	0.21	0.14	Corcept Therapeutics GAAP EPS of $0.25 beats by $0.03, revenue of $146.81M beats by $5.61M [5/1/2024 4:52 PM]	25.06	1.18 (4.94%)	26.15	2.27 (9.51%)	20.84 - 34.28	2,010,746	1,490,000	1,748
Corcept Therapeutics GAAP EPS of $0.25 beats by $0.03, revenue of $146.81M beats by $5.61M [5/1/2024 4:52 PM]
15-02-2024	AH		CORT	Corcept Therapeutics Incorporated	2,380	0.28	0.25	0.14	Corcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M [2/15/2024 4:23 PM]	22.73	-1.73 (-7.07%)	26.05	1.59 (6.50%)	17.86 - 34.28	1,972,934	1,370,000	4,670
Corcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M [2/15/2024 4:23 PM]
01-11-2023	AH		CORT	Corcept Therapeutics Incorporated	2,800	0.28	0.22	0.30	Corcept Therapeutics GAAP EPS of $0.28 beats by $0.06, revenue of $123.6M beats by $3.88M [11/1/2023 4:28 PM]	25.30	-2.79 (-9.93%)	28.09	0.0 (0.00%)	17.86 - 34.28	2,745,612	630,000	22,323
Corcept Therapeutics GAAP EPS of $0.28 beats by $0.06, revenue of $123.6M beats by $3.88M [11/1/2023 4:28 PM]
02-08-2023	AH		CORT	Corcept Therapeutics Incorporated	2,590	0.25	0.15	0.24	Corcept Therapeutics GAAP EPS of $0.25 beats by $0.10, revenue of $117.7M beats by $8.1M [8/2/2023 4:52 PM]	31.27	6.26 (25.03%)	25.98	0.97 (3.88%)	17.86 - 31.90	4,567,161	540,000	5,364
Corcept Therapeutics GAAP EPS of $0.25 beats by $0.10, revenue of $117.7M beats by $8.1M [8/2/2023 4:52 PM]
03-05-2023	AH	4:05 PM ET (May 3)	CORT	Corcept Therapeutics Incorporated	2,310	0.14	0.20	0.20	Corcept Therapeutics GAAP EPS of $0.14 misses by $0.05, revenue of $105.7M beats by $0.79M [5/3/2023 4:15 PM]	24.02	0.92 (4.00%)	23.10	0.0 (0.00%)	17.19 - 30.14	893,165	770,000	22,852
Corcept Therapeutics GAAP EPS of $0.14 misses by $0.05, revenue of $105.7M beats by $0.79M [5/3/2023 4:15 PM]
28-02-2023	AH	4:05 PM ET (Feb 28)	CORT	Corcept Therapeutics Incorporated	2,350	0.14	0.23	0.26	Corcept Therapeutics GAAP EPS of $0.15 misses by $0.08, revenue of $103M misses by $2.08M [2/28/2023 5:08 PM]	19.88	-0.95 (-4.58%)	20.83	0.0 (0.00%)	17.19 - 30.14	1,664,862	730,000	51,550
Corcept Therapeutics GAAP EPS of $0.15 misses by $0.08, revenue of $103M misses by $2.08M [2/28/2023 5:08 PM]
03-11-2022	AH	4:05 PM ET (Nov 3)	CORT	Corcept Therapeutics Incorporated	3,210	0.30	0.23	0.24	Corcept Therapeutics GAAP EPS of $0.30, revenue of $101.7M [11/3/2022 5:23 PM]	25.57	-2.95 (-10.34%)	26.99	-1.53 (-5.36%)	15.82 - 30.14	1,352,168	680,000	378
Corcept Therapeutics GAAP EPS of $0.30, revenue of $101.7M [11/3/2022 5:23 PM] Corcept Therapeutics (CORT) Tops Q3 Earnings Estimates [Nov-03-22 07:25PM] Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update [Nov-03-22 04:05PM]
03-08-2022	AH	4:05 PM ET (Aug 3)	CORT	Corcept Therapeutics Incorporated	2,860	0.24	0.24	0.21	Corcept Therapeutics GAAP EPS of $0.24, revenue of $103.4M [8/3/2022 4:11 PM]	28.38	-0.33 (-1.17%)	28.72	0.01 (0.03%)	15.82 - 29.93	997,415	620,000	18,364
Corcept Therapeutics GAAP EPS of $0.24, revenue of $103.4M [8/3/2022 4:11 PM] Corcept Therapeutics Q2 2022 Earnings Preview [8/3/2022 5:35 PM] Corcept Therapeutics (CORT) Q2 2022 Earnings Call Transcript [Aug-04-22 12:30AM] Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates [Aug-03-22 05:35PM] Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update [Aug-03-22 04:05PM]
05-05-2022	AH	4:05 PM ET (May 5)	CORT	Corcept Therapeutics Incorporated	2,340	0.20	0.23	0.18	Corcept Therapeutics GAAP EPS of $0.20 misses by $0.03, revenue of $93.69M misses by $4.91M [5/5/2022 4:16 PM]	19.11	-2.20 (-10.34%)	21.32	0.0 (0.00%)	15.82 - 25.68	1,716,252	920,000	3,005
Corcept Therapeutics GAAP EPS of $0.20 misses by $0.03, revenue of $93.69M misses by $4.91M [5/5/2022 4:16 PM] Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update [May-05-22 04:05PM] Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates [May-05-22 06:05PM] Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates [May-06-22 11:11AM]
15-02-2022	AH	4:05 PM ET (Feb 15)	CORT	Corcept Therapeutics Incorporated	2,310	0.26	0.22	0.20	Corcept Therapeutics Non-GAAP EPS of $0.35 in-line, revenue of $98.8M misses by $1.77M [2/15/2022 4:12 PM]	22.84	2.53 (12.46%)	20.35	0.04 (0.20%)	15.82 - 28.25	1,451,587	760,000	300
Corcept Therapeutics Non-GAAP EPS of $0.35 in-line, revenue of $98.8M misses by $1.77M [2/15/2022 4:12 PM] Corcept climbs after Q4 earnings amid positive views from analysts [2/16/2022 2:50 PM] Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update [Feb-15-22 04:05PM] Corcept Therapeutics (CORT) Q4 Earnings Beat Estimates [Feb-15-22 05:55PM] Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss [Feb-16-22 09:54AM]
03-11-2021	AH	4:05 PM ET (Nov 3)	CORT	Corcept Therapeutics Incorporated	2,110	0.24	0.19	0.17	Corcept Therapeutics EPS beats by $0.09, misses on revenue [11/3/2021 4:12 PM]	20.07	1.83 (10.01%)	18.50	0.26 (1.43%)	16.67 - 31.18	695,565	630,000	214,220
Corcept Therapeutics EPS beats by $0.09, misses on revenue [11/3/2021 4:12 PM] Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update [Nov-03-21 04:05PM] Corcept Therapeutics (CORT) Q3 Earnings Top Estimates [Nov-03-21 06:15PM] Corcept Therapeutics Incorporated (CORT) Q3 2021 Earnings Call Transcript [Nov-03-21 09:01PM] Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss [Nov-04-21 09:48AM]
29-07-2021	AH	4:10 PM ET (Jul 29)	CORT	Corcept Therapeutics Incorporated	2,330	0.21	0.14	0.23	Corcept Therapeutics EPS beats by $0.13, beats on revenue [7/29/2021 4:25 PM]	20.74	0.45 (2.19%)	20.29	0.0 (0.00%)	12.20 - 31.18	557,954	550,000	9,638
Corcept Therapeutics EPS beats by $0.13, beats on revenue [7/29/2021 4:25 PM] Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update [Jul-29-21 04:05PM] Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates [Jul-29-21 06:35PM] Corcept Therapeutics Incorporated (CORT) Q2 2021 Earnings Call Transcript [Jul-30-21 04:32AM] Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y [Jul-30-21 01:33PM]
06-05-2021	AH	4:05 PM ET (May 6)	CORT	Corcept Therapeutics Incorporated	2,590	0.18	0.21	0.25	Corcept Therapeutics EPS beats by $0.01, misses on revenue [5/6/2021 4:21 PM]	21.12	-0.59 (-2.72%)	21.18	-0.53 (-2.44%)	12.20 - 31.18	630,432	460,000	5,443
Corcept Therapeutics EPS beats by $0.01, misses on revenue [5/6/2021 4:21 PM] Corcept suspends mid-stage NASH study after elevated liver enzymes in patients [5/6/2021 5:02 PM] Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy? [May-05-21 06:32AM] Corcept Therapeutics, Inc. to Host Earnings Call [May-06-21 02:45PM] Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer [May-06-21 04:01PM] Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results [May-06-21 04:10PM] Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH) [May-06-21 04:05PM] Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates [May-06-21 05:20PM] Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript [May-07-21 06:31AM] Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients [May-07-21 06:56AM] Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y [May-07-21 10:09AM] Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1 [May-07-21 12:17PM]
08-02-2021	AH	4:05 PM ET (Feb 8)	CORT	Corcept Therapeutics Incorporated	3,420	N/A	0.16	0.24	Corcept Therapeutics reports preliminary Q4 results [2/8/2021 4:13 PM]	29.62	-0.94 (-3.08%)	29.07	-1.49 (-4.88%)	9.70 - 31.18	879,311	609,446	4,204
Corcept Therapeutics reports preliminary Q4 results [2/8/2021 4:13 PM]
03-11-2020	AH	4:05 PM ET (Nov 3)	CORT	Corcept Therapeutics Incorporated	1,940	0.17	0.21	0.22	Corcept Therapeutics EPS beats by $0.01, misses on revenue [11/3/2020 4:07 PM]	18.19	0.39 (2.19%)	16.64	-1.16 (-6.52%)	9.70 - 23.48	922,429	838,698	956

04-08-2020	AH	4:05 PM ET (Aug 4)	CORT	Corcept Therapeutics Incorporated	1,710	0.23	0.20	0.17	Corcept Therapeutics EPS beats by $0.01, misses on revenue [8/4/2020 4:12 PM]	14.47	-1.22 (-7.78%)	13.70	-1.99 (-12.68%)	9.70 - 18.52	2,560,925	964,912	39,223